BioNTech SE
BNTXHealthcare|Biotechnology|Germany
$91.28
+0.10 (+0.11%)
DCF (FCF)
$259.67
Tangible Book
$80.37
About
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Stock Price
-2.3%(1Y)
Pipeline Summary
117 total trials65
Phase 1
63
Phase 2
27
Phase 3
1
Phase 4
Completed: 42Terminated: 17Recruiting: 38Active: 15Withdrawn: 3NOT_YET_RECRUITING: 2
Active Trials (53)
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
NCT07392372HIV -1 Infection
Phase 1Recruiting
Enrollment: 61 participants
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839COVID-19
Phase 3Recruiting
Enrollment: 25,500 participants
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378Colorectal Cancer Stage II
Phase 2Recruiting
Enrollment: 327 participants
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
NCT05557591Advanced Non-Small Cell Lung Cancer
Phase 2Active
Enrollment: 51 participants
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
Phase 2Phase 3Recruiting
Enrollment: 990 participants
BioScore
7.6/10
Buy
Ownership
Recent News
2026-03-31 11:31:24
2026-03-24 11:00:02
2026-03-11 17:01:15
2026-03-11 17:00:31
2026-03-11 16:31:55
Data last updated: Apr 7, 2026, 03:33 AM